Herceptest: HER2 expression and gene amplification in non-small cell lung cancer

International Journal of Cancer

Volumn 92, Issue 4, 2001, Pages 480-483

  Cox, G ^a   Vyberg, M ^b   Melgaard, B ^a   Askaa, J ^a   Oster, A ^c   O'Byrne, K J ^a  

^a LEICESTER ROYAL INFIRMARY   (United Kingdom)

^b AALBORG UNIVERSITY HOSPITAL   (Denmark)

^c NONE

Author keywords

HER2; HerceptTest; Immunohistochemistry; Non small cell lung cancer; Prognosis

Indexed keywords

TRASTUZUMAB; TYROSINE KINASE RECEPTOR;

ARTICLE; BREAST CANCER; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; ONCOGENE NEU; POLYPLOIDY; PRIORITY JOURNAL;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CELL MEMBRANE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; NEOPLASMS, SQUAMOUS CELL; PLOIDIES; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES;

EID: 0035874065     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.1214     Document Type: Article

References (22)

1. The erbB/HER type 1 tyrosine kinase receptor family
2. Expression of the c-erbB-2 oncoprotein: A prognostic indicator in human breast cancer
3. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas
4. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
5. Recombinant humanized anti-HER2 antibody (HERCEPTIN®) enhances the activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts
6. Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER+/MBC) markedly increases anticancer activity: A randomised, multinational controlled phase III trial
7. neu expression in human lung adenocarcinomas predicts shortened survival
8. Immunocytochemical markers in stage I lung cancer: Relevance to prognosis
9. neu) in human non-small cell carcinomas of the lung
10. Prognostic value of c-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma
11. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology and oncoprotein expression
12. Non-small cell lung cancer: C-erbB-2 overexpression correlates with low angiogenesis and poor prognosis
13. Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: Amphiregulin and microvessel count are independent prognostic indicators of survival
14. Prediction of recurrence by quantification of p185neu protein in non-small-cell lung cancer tissue
15. Localized adenocarcinoma of the lung: Oncogene expression of erbB-2 and p53 in 150 patients
16. HER-2 breast assay, linked to Herceptin, wins FDA's okay
17. Specificity of HercepTest in determining HER2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system
18. The World Health Organisation histological typing of lung cancer
19. Revisions in the international system for staging lung cancer
20. HER-2/neu protein expression in breast cancer evaluated by immunohistochemistry. A study of interlaboratory agreement
21. Increased HER2 with US Food and Drug Administration-approved antibody
22. Testing for erbB-2 by immunohistochemistry in breast cancer